Trident Techlabs Ltd
TECHLABSTrident Techlabs Ltd's earnings have outrun its stock. EPS grew +22.7% in a year against a −73.7% price move.
The sharpest disagreement: profits are rising, but only 38% of the last 3 years' profit arrived as operating cash — the gap between the P&L and the bank account is the thing to watch.
The price is in a downtrend (51 weeks in) while the P/E sits at the 13th percentile of its own 2-year range. Underneath, the last four quarters read improving — profit +266.7% year on year, and 38% of the last 3 years' profit arrived as cash. What settles it: whether the cash starts following the profit.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Trident Techlabs Ltd trades at ₹167, in a downtrend and 51 weeks into that stage. That is −56.7% against its own 200-day average. It sits at 0% of a 52-week range of ₹167 to ₹608. On relative strength it is currently behind the NIFTY 500 on a trailing-13-week view (20 weeks and counting).
Today the stock is in a downtrend — week 51 of stage 4, confirmed. At ₹167 it trades −56.7% versus its 200-day average and sits at 0% of its 52-week range (₹167–₹608).
Against the market, two honest reads. Cumulative: over the last 2.2 years the stock moved +62% while the NIFTY 500 moved +8% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (20 weeks and counting; last ahead the week of 2025-11-07) — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Trident Techlabs Ltd trades at 14.9× P/E, near the bottom of its own range — cheaper only 13% of the time. Its long-run median P/E is 48.8×, measured across 2.2 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 14.9× is near the bottom of its own range — cheaper only 13% of the time, against a long-run median of 48.8× measured over 2.2 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
One caveat before moving on: margins are the best this company has ever printed — cheap against its own history on record margins is not the same thing as cheap. If profitability mean-reverts, today's multiple is higher than it looks.
Why the multiple sits where it does: over the past year annual EPS moved +22.7% against a −73.7% price move — earnings outran the price, pushing the multiple DOWN its own range.
Put together: the multiple is low against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Trident Techlabs Ltd reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read. The read is built from 4 quarters across 1 curve, on partial evidence.
Why it matters: with too little history, an honest page says so instead of guessing a trajectory.
One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.
Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.
Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +5.5% | +36.9% | — | — |
| Profit | +33.3% | +128.9% | — | — |
| EPS | +22.7% | +42.1% | — | — |
| Share price | −73.7% | — | — | — |
4-Factor Sector Score
46.1/100 — rank 61 of 64 in IT - Software · 40% evidence confidence · provisional, ranked below fully-evidenced peers
Trident Techlabs Ltd scores 46.1 out of 100 against the 64 companies it is compared with in IT - Software, ranking 61. Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
The four contributions add to the total exactly: 16 + 16.1 + 10.8 + 3.2 = 46.1. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Trident Techlabs Ltd reported ₹64.0 Cr of revenue in the Sep 25 quarter, +204.8% year on year. Over 4 years it has compounded at 28.8% a year. The last full year, FY25, came in at ₹77.0 Cr. The last four reported quarters add to ₹205 Cr.
FY25 revenue came in at ₹77.0 Cr (+5.5% on the year), capping 4 years at 28.8% compound. The latest quarter (Sep 25) printed ₹64.0 Cr, +204.8% year on year.
Pace check: the last four quarters averaged +241.5% growth against the decade's 28.8% — the current year is running faster than its own long-run rate.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Trident Techlabs Ltd's operating margin is 27.0% in the Sep 25 quarter, −2.0 percentage points against the same quarter a year ago. That is the widest this company has ever printed on a full-year basis. Across the last four quarters the operating margin has moved +45.0 percentage points. Across 5 fiscal years the operating margin has ranged 15.0% to 25.0%.
The latest quarter's operating margin is 27.0%, −2.0 pp against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 15.0%–25.0%, and FY25's 25.0% is the top of that band — a record year.
Why the margin moved: operating margin went +44.7 pp year on year while gross margin went −34.1 pp — the gain came mostly from the gross line: input costs and pricing.
Worth repeating from the valuation section: cheap against its own history on record margins is not the same thing as cheap — a record margin flatters every ratio built on top of it.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Trident Techlabs Ltd earned ₹11.0 Cr of net profit in the Sep 25 quarter, +266.7% year on year. Full-year FY25 profit was ₹12.0 Cr. That is 17.2% of the quarter's revenue. The same quarter a year earlier lost ₹3.0 Cr.
Sep 25 profit was ₹11.0 Cr, +266.7% year on year. On the full year, FY25 printed ₹12.0 Cr (+33.3%).
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 38% of Trident Techlabs Ltd's reported profit arrived as operating cash — a gap worth watching. In FY25 that was ₹16.0 Cr of operating cash against ₹12.0 Cr of profit. After ₹3.0 Cr of capital spending, ₹13.0 Cr was left as free cash.
FY25: operating cash of ₹16.0 Cr against reported profit of ₹12.0 Cr, leaving free cash of ₹13.0 Cr after ₹3.0 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 38% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
🚨 Why conversion sits at 38%: the cash cycle stretched 202 days between FY21 and FY25 — more of each rupee of profit waits inside the cycle before arriving. Less than 70% of profit arriving as cash is the thing to watch on this page.
Router verdict: conversion is below par and the cash cycle has stretched 202 days — the next section's job is to find where the cash is stuck.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Trident Techlabs Ltd's cash conversion cycle runs 124 days in FY25, up from −78 days in FY21. Capital spending ran ₹4.0 Cr over the last 3 years. At FY25 sales of ₹77.0 Cr each day of that cycle holds about ₹0.2 Cr, so roughly ₹26.0 Cr sits inside the business at any moment.
FY25: debtors at 302 days, inventory at 44 days — roughly 1.4 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 124 days, looser than FY21's −78.
The full loop: cash goes out to suppliers and production on day 0; stock waits 44 days to sell; customers pay about 302 days after that; and suppliers themselves are paid at 222 days — netting out to the 124-day cycle.
In money terms: at FY25 sales of ₹77.0 Cr, each day of the cycle holds about ₹0.2 Cr — so the 124-day loop keeps roughly ₹26.0 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹4.0 Cr over the last 3 fiscal years against ₹2.0 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹0.0 Cr (FY25) — capacity paid for but not yet earning.
The synthesis: the working-capital loop is the cash sink the router flagged — watch the cycle, not the P&L.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
Trident Techlabs Ltd earns a ROCE of 27% in FY25. That is up from a trough of 9% in FY22. Return on invested capital clears the cost of that capital by −1.4 percentage points, so growth here is not yet paying for the capital it uses. The wiring behind it is 15.6% net margin on 0.85× asset turns.
FY25 ROCE is 27%, recovered from a FY22 trough of 9% — the full ladder below shows the fall and the climb, undoctored.
🚨 Why the return is what it is — the wiring (FY25): 15.6% net margin × 0.85× asset turns × 1.57× balance-sheet leverage ≈ 20.8% on equity. Margin is doing the heavy lifting; leverage is modest — this is an earned return, not a borrowed one.
The capstone test — ROIC − WACC: 10.6% − 12.0% = a −1.4 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. Negative — growth at these returns destroys value until the returns recover.
Debt Debt-to-equity says how much of the business is funded by borrowings; interest cover says how many times operating profit pays the interest bill. Low and high, respectively, is the safe corner.
Trident Techlabs Ltd carries ₹13.0 Cr of borrowings against ₹58.0 Cr of equity in FY25, a debt-to-equity of 0.22. Operating profit covers the interest bill 6×. Over 4 years borrowings went from ₹30.0 Cr to ₹13.0 Cr. Capital spending ran ₹4.0 Cr across the last 3 of those years.
FY25: borrowings of ₹13.0 Cr against equity of ₹58.0 Cr — a debt-to-equity of 0.22. Operating profit covers the interest bill 6×. Over 4 years borrowings went from ₹30.0 Cr to ₹13.0 Cr while capital spending ran ₹4.0 Cr in just the last 3 — the build-out is being paid for out of cash, not debt.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
Domestic institutions cut 12.4 points of Trident Techlabs Ltd over 4 quarters, the biggest move on the register. That takes domestic institutions to 0.0% of the company. Foreign institutions moved −1.7 points over the same window, to 0.0%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Domestic institutions: −12.4 points over 4 quarters to 0.0%; Foreign institutions: −1.7 points over 4 quarters to 0.0%; Promoters: +0.0 points over 4 quarters to 68.0%.
🚨 Why the register moved: domestic institutions drove it (−12.4 points), alongside foreign institutions (−1.7 points) — distribution into the market’s bid.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Trident Techlabs Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Coforge LtdCOFORGE | 76.7/100Favorable setup100% evidence | LEADER | 30.0/35 Revenue 35.7% · PAT 66.5% · OPM change 3 pp 100% evidence | 15.7/25 ROCE 23.5% · OPM 19% 100% evidence | 12.7/20 P/E 41.9× · PEG 0.57 100% evidence | 18.3/20 RS sector 11.9% · RS bench 15.3% · 1Y 12.8%12 of 12 weeks ahead 100% evidence |
| Exact sum: 30 + 15.7 + 12.7 + 18.3 = 76.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 2Silver Touch Technologies LtdSILVERTUC | 73.4/100Favorable setup93% evidence | LEADER | 30.2/35 Revenue 21.1% · PAT 86.4% · OPM change 8 pp 100% evidence | 17.4/25 ROCE 29.8% · OPM 22% 100% evidence | 10.2/20 P/E 63.7× · PEG 1.11 65% evidence | 15.6/20 RS sector 52.8% · RS bench 60.7% · 1Y 183.3%12 of 12 weeks ahead 100% evidence |
| Exact sum: 30.2 + 17.4 + 10.2 + 15.6 = 73.4 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 3NINtec Systems LtdNINSYS | 65.5/100Favorable setup80% evidence | LEADER | 20.2/35 Revenue 21.6% · PAT 18.8% · OPM change 4.2 pp 95% evidence | 21.8/25 ROCE 55% · OPM 25.9% 95% evidence | 9.2/20 P/E 40.9× · PEG — 15% evidence | 14.3/20 RS sector 40.8% · RS bench 46% · 1Y 77.8%12 of 12 weeks ahead 100% evidence |
| Exact sum: 20.2 + 21.8 + 9.2 + 14.3 = 65.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4Cigniti Technologies LtdCIGNITITEC | 63.7/100Mixed-positive evidence79% evidence | 23.4/35 Revenue 14% · PAT 96.1% · OPM change 2 pp 56% evidence | 16.2/25 ROCE 34.1% · OPM 18% 75% evidence | 16.0/20 P/E 11.4× · PEG 0.61 100% evidence | 8.1/20 RS sector -9.4% · RS bench -15% · 1Y -16.2%0 of 12 weeks ahead to 2026-05-17 100% evidence | |
| Exact sum: 23.4 + 16.2 + 16 + 8.1 = 63.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5Tech Mahindra LtdTECHM | 63.5/100Mixed-positive evidence94% evidence | BREAKING OUT | 21.2/35 Revenue 10.9% · PAT 14.3% · OPM change 3 pp 100% evidence | 16.2/25 ROCE 23.1% · OPM 17% 100% evidence | 10.6/20 P/E 30.1× · PEG 0.76 100% evidence | 15.5/20 RS sector 16% · RS bench 7.2% · 1Y 10.3%6 of 11 weeks ahead 70% evidence |
| Exact sum: 21.2 + 16.2 + 10.6 + 15.5 = 63.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Datamatics Global Services LtdDATAMATICS | 63.3/100Mixed-positive evidence94% evidence | BREAKING OUT | 21.1/35 Revenue 13.1% · PAT 1.9% · OPM change 4 pp 100% evidence | 16.1/25 ROCE 20.8% · OPM 20% 100% evidence | 11.2/20 P/E 20.2× · PEG 0.58 100% evidence | 14.9/20 RS sector 10.8% · RS bench 4.8% · 1Y -12.4%7 of 10 weeks ahead 70% evidence |
| Exact sum: 21.1 + 16.1 + 11.2 + 14.9 = 63.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7Sasken Technologies LtdSASKEN | 62.4/100Mixed-positive evidence100% evidence | LEADER | 30.8/35 Revenue 67.8% · PAT 67.4% · OPM change 4 pp 100% evidence | 8.0/25 ROCE 9.9% · OPM 9% 100% evidence | 9.8/20 P/E 40.6× · PEG 0.68 100% evidence | 13.8/20 RS sector 22.8% · RS bench 27.4% · 1Y 37.2%12 of 12 weeks ahead 100% evidence |
| Exact sum: 30.8 + 8 + 9.8 + 13.8 = 62.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8Sahana Systems LtdSAHANA | 62.4/100Mixed-positive evidence70% evidence | BASING | 21.5/35 Revenue 100% · PAT 100% · OPM change -3 pp 48% evidence | 19.9/25 ROCE 39.8% · OPM 29% 95% evidence | 14.5/20 P/E 12.3× · PEG — 50% evidence | 6.5/20 RS sector -19.6% · RS bench -3.1% · 1Y -33.9%0 of 12 weeks ahead 100% evidence |
| Exact sum: 21.5 + 19.9 + 14.5 + 6.5 = 62.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 9String Metaverse Ltd534535 | 62.2/100Mixed-positive evidence82% evidence | BASING | 27.2/35 Revenue 100% · PAT 100% · OPM change 0 pp 95% evidence | 15.7/25 ROCE 41.6% · OPM 11% 76% evidence | 14.7/20 P/E 7.9× · PEG — 50% evidence | 4.6/20 RS sector -53.3% · RS bench -43.5% · 1Y -70.1%0 of 12 weeks ahead 100% evidence |
| Exact sum: 27.2 + 15.7 + 14.7 + 4.6 = 62.2 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -53.3% and the one-year return is -70.1%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 10TAC Infosec LtdTAC | 62.0/100Mixed-positive evidence66% evidence | ASLEEP | 25.6/35 Revenue 76.4% · PAT 59.4% · OPM change 1.6 pp 71% evidence | 20.9/25 ROCE 38.1% · OPM 48.2% 95% evidence | 9.3/20 P/E 35.3× · PEG — 15% evidence | 6.2/20 RS sector -12.3% · RS bench -20% · 1Y 4.7%1 of 10 weeks ahead 70% evidence |
| Exact sum: 25.6 + 20.9 + 9.3 + 6.2 = 62 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -12.3% and the one-year return is 4.7%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 11IZMO LtdIZMO | 60.8/100Mixed-positive evidence81% evidence | BREAKING OUT | 24.1/35 Revenue 24.7% · PAT 10.2% · OPM change 8 pp 95% evidence | 14.2/25 ROCE 12.6% · OPM 25% 95% evidence | 6.7/20 P/E 26.2× · PEG — 50% evidence | 15.8/20 RS sector 30.3% · RS bench 9.6% · 1Y 148.4%9 of 10 weeks ahead 70% evidence |
| Exact sum: 24.1 + 14.2 + 6.7 + 15.8 = 60.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 12ASM Technologies LtdASMTEC | 60.8/100Mixed-positive evidence69% evidence | 28.1/35 Revenue 67.8% · PAT 89.5% · OPM change 2 pp 95% evidence | 16.4/25 ROCE 27% · OPM 23% 76% evidence | 8.7/20 P/E 91.8× · PEG — 15% evidence | 7.6/20 RS sector -5.8% · RS bench -18.4% · 1Y -22.1%0 of 12 weeks ahead to 2026-03-08 70% evidence | |
| Exact sum: 28.1 + 16.4 + 8.7 + 7.6 = 60.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 13InfoBeans Technologies LtdINFOBEAN | 59.2/100Mixed-positive evidence87% evidence | TURNING | 26.5/35 Revenue 35.5% · PAT 60.4% · OPM change 0 pp 95% evidence | 16.9/25 ROCE 29.2% · OPM 21% 95% evidence | 9.6/20 P/E 18.5× · PEG — 50% evidence | 6.2/20 RS sector -8.1% · RS bench -4.1% · 1Y 14.9%5 of 12 weeks ahead 100% evidence |
| Exact sum: 26.5 + 16.9 + 9.6 + 6.2 = 59.2 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -8.1% and the one-year return is 14.9%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 14Softtech Engineers LtdSOFTTECH | 59.0/100Mixed-positive evidence80% evidence | FADING | 25.2/35 Revenue 35.8% · PAT 100% · OPM change -0.1 pp 95% evidence | 12.1/25 ROCE 6.2% · OPM 27.2% 95% evidence | 8.7/20 P/E 118× · PEG — 15% evidence | 13.0/20 RS sector 13.9% · RS bench 18% · 1Y 13.4%9 of 12 weeks ahead 100% evidence |
| Exact sum: 25.2 + 12.1 + 8.7 + 13 = 59 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 15Hypersoft Technologies LtdHYPERSOFT | 58.3/100Thin evidence · provisional52% evidence | 25.5/35 Revenue 100% · PAT 100% · OPM change 2.9 pp 71% evidence | 11.8/25 ROCE 20.6% · OPM 14% 76% evidence | 8.6/20 P/E 431× · PEG — 15% evidence | 12.4/20 RS sector — · RS bench 61.7% · 1Y 28.6%4 of 12 weeks ahead to 2026-03-08 25% evidence | |
| Exact sum: 25.5 + 11.8 + 8.6 + 12.4 = 58.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 16Infosys LtdINFY | 58.1/100Mixed-positive evidence82% evidence | TURNING | 18.2/35 Revenue 11.2% · PAT 11.1% · OPM change 0 pp 95% evidence | 20.1/25 ROCE 40% · OPM 24% 76% evidence | 14.0/20 P/E 15.2× · PEG — 50% evidence | 5.8/20 RS sector -18.7% · RS bench -15.8% · 1Y -17.8%0 of 12 weeks ahead 100% evidence |
| Exact sum: 18.2 + 20.1 + 14 + 5.8 = 58.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 17BLS E-Services LtdBLSE | 57.9/100Mixed-positive evidence75% evidence | LEADER | 18.8/35 Revenue 71.2% · PAT 9.4% · OPM change 0 pp 95% evidence | 10.5/25 ROCE 17% · OPM 7% 76% evidence | 9.0/20 P/E 49.1× · PEG — 15% evidence | 19.6/20 RS sector 48.9% · RS bench 54.1% · 1Y 72.6%12 of 12 weeks ahead 100% evidence |
| Exact sum: 18.8 + 10.5 + 9 + 19.6 = 57.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 18Saksoft LtdSAKSOFT | 57.7/100Mixed-positive evidence100% evidence | BREAKING OUT | 17.9/35 Revenue 8.2% · PAT 13% · OPM change 0 pp 100% evidence | 15.6/25 ROCE 25.5% · OPM 18% 100% evidence | 13.2/20 P/E 16.4× · PEG 0.6 100% evidence | 11.0/20 RS sector -7.5% · RS bench -4.8% · 1Y -23.6%9 of 12 weeks ahead 100% evidence |
| Exact sum: 17.9 + 15.6 + 13.2 + 11 = 57.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 19Ksolves India LtdKSOLVES | 57.5/100Mixed-positive evidence87% evidence | BASING | 18.0/35 Revenue 16% · PAT 16.7% · OPM change 3.9 pp 95% evidence | 20.6/25 ROCE 131% · OPM 30.3% 95% evidence | 13.7/20 P/E 17.7× · PEG — 50% evidence | 5.2/20 RS sector -12% · RS bench -8.7% · 1Y -12.7%0 of 12 weeks ahead 100% evidence |
| Exact sum: 18 + 20.6 + 13.7 + 5.2 = 57.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 20Expleo Solutions LtdEXPLEOSOL | 57.3/100Mixed-positive evidence81% evidence | ASLEEP | 20.9/35 Revenue 10.4% · PAT 39.4% · OPM change 4 pp 95% evidence | 15.8/25 ROCE 24.2% · OPM 15% 95% evidence | 13.8/20 P/E 8.6× · PEG — 50% evidence | 6.8/20 RS sector -12.4% · RS bench -11% · 1Y -26.7%3 of 10 weeks ahead 70% evidence |
| Exact sum: 20.9 + 15.8 + 13.8 + 6.8 = 57.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 21Subex LtdSUBEXLTD | 56.6/100Mixed-positive evidence65% evidence | BREAKING OUT | 24.4/35 Revenue 2.8% · PAT 100% · OPM change 13 pp 95% evidence | 10.3/25 ROCE 12.8% · OPM 19% 95% evidence | 9.9/20 P/E 24.2× · PEG — 15% evidence | 12.0/20 RS sector — · RS bench 21.2% · 1Y —5 of 5 weeks ahead 25% evidence |
| Exact sum: 24.4 + 10.3 + 9.9 + 12 = 56.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 22LTM LtdLTM | 56.3/100Mixed-positive evidence100% evidence | TURNING | 17.3/35 Revenue 13.9% · PAT 10% · OPM change 1 pp 100% evidence | 17.9/25 ROCE 29.6% · OPM 18% 100% evidence | 11.3/20 P/E 24.9× · PEG 1.18 100% evidence | 9.8/20 RS sector -9.8% · RS bench -6.8% · 1Y -5.9%1 of 12 weeks ahead 100% evidence |
| Exact sum: 17.3 + 17.9 + 11.3 + 9.8 = 56.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 23R Systems International LtdRSYSTEMS | 55.4/100Mixed-positive evidence100% evidence | ASLEEP | 18.8/35 Revenue 24.1% · PAT -1% · OPM change 3 pp 100% evidence | 16.4/25 ROCE 19.5% · OPM 18% 100% evidence | 18.2/20 P/E 13.6× · PEG 0.26 100% evidence | 2.0/20 RS sector -31.2% · RS bench -29.2% · 1Y -42.2%0 of 12 weeks ahead 100% evidence |
| Exact sum: 18.8 + 16.4 + 18.2 + 2 = 55.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 24Tanla Platforms LtdTANLA | 53.7/100Mixed-positive evidence94% evidence | BREAKING OUT | 14.5/35 Revenue 13.2% · PAT 9.9% · OPM change 0 pp 100% evidence | 16.5/25 ROCE 26.3% · OPM 16% 100% evidence | 13.2/20 P/E 14.5× · PEG 1.21 100% evidence | 9.5/20 RS sector -11% · RS bench 4% · 1Y -5.9%9 of 10 weeks ahead 70% evidence |
| Exact sum: 14.5 + 16.5 + 13.2 + 9.5 = 53.7 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 25TechNVision Ventures LtdTECHNVISN | 53.3/100Mixed-positive evidence74% evidence | ASLEEP | 26.0/35 Revenue 23.4% · PAT 100% · OPM change 2.9 pp 95% evidence | 5.5/25 ROCE 12.9% · OPM 5.2% 95% evidence | 8.5/20 P/E 1093× · PEG — 15% evidence | 13.3/20 RS sector 32.1% · RS bench -7.8% · 1Y 30.3%0 of 7 weeks ahead 70% evidence |
| Exact sum: 26 + 5.5 + 8.5 + 13.3 = 53.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 26Danlaw Technologies India Ltd532329 | 53.2/100Mixed-positive evidence60% evidence | 15.7/35 Revenue 10.9% · PAT 14% · OPM change 0.8 pp 95% evidence | 15.5/25 ROCE 27.2% · OPM 13.4% 76% evidence | 9.6/20 P/E 26.6× · PEG — 15% evidence | 12.4/20 RS sector — · RS bench 65.9% · 1Y — 25% evidence | |
| Exact sum: 15.7 + 15.5 + 9.6 + 12.4 = 53.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 27Xchanging Solutions LtdXCHANGING | 52.8/100Mixed-positive evidence81% evidence | ASLEEP | 18.6/35 Revenue 8.4% · PAT 13.2% · OPM change 1 pp 95% evidence | 15.4/25 ROCE 18% · OPM 34% 95% evidence | 13.4/20 P/E 11.7× · PEG — 50% evidence | 5.4/20 RS sector -23.6% · RS bench -14.3% · 1Y -26%1 of 10 weeks ahead 70% evidence |
| Exact sum: 18.6 + 15.4 + 13.4 + 5.4 = 52.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 28Seshaasai Technologies LtdSTYL | 52.5/100Mixed-positive evidence73% evidence | BREAKING OUT | 12.8/35 Revenue 6.7% · PAT 20.6% · OPM change 0 pp 100% evidence | 17.1/25 ROCE 27.7% · OPM 23% 100% evidence | 12.6/20 P/E 25× · PEG 0.81 65% evidence | 10.0/20 RS sector — · RS bench — · 1Y —9 of 10 weeks ahead 0% evidence |
| Exact sum: 12.8 + 17.1 + 12.6 + 10 = 52.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 29Blue Cloud Softech Solutions LtdBLUECLOUDS | 52.5/100Mixed-positive evidence69% evidence | 22.0/35 Revenue 41.1% · PAT 36.2% · OPM change 10 pp 95% evidence | 12.8/25 ROCE 14.2% · OPM 20% 76% evidence | 9.4/20 P/E 32.9× · PEG — 15% evidence | 8.3/20 RS sector -3.8% · RS bench -16.1% · 1Y -24.4%1 of 12 weeks ahead to 2026-03-08 70% evidence | |
| Exact sum: 22 + 12.8 + 9.4 + 8.3 = 52.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 30AvenuesAI LtdCCAVENUE | 52.2/100Mixed-positive evidence93% evidence | BREAKING OUT | 21.0/35 Revenue 100% · PAT 43.8% · OPM change -2.3 pp 100% evidence | 8.1/25 ROCE 7.7% · OPM 3.7% 100% evidence | 15.1/20 P/E 18.1× · PEG 0.37 65% evidence | 8.0/20 RS sector -10.1% · RS bench -6.9% · 1Y 1.4%8 of 12 weeks ahead 100% evidence |
| Exact sum: 21 + 8.1 + 15.1 + 8 = 52.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 31Dynacons Systems & Solutions LtdDSSL | 52.2/100Mixed-positive evidence87% evidence | FADING | 16.9/35 Revenue 10.5% · PAT 16.2% · OPM change 3 pp 95% evidence | 15.4/25 ROCE 29.8% · OPM 13% 95% evidence | 7.9/20 P/E 18× · PEG — 50% evidence | 12.0/20 RS sector 5.1% · RS bench 9.4% · 1Y 20.4%10 of 12 weeks ahead 100% evidence |
| Exact sum: 16.9 + 15.4 + 7.9 + 12 = 52.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 32Birlasoft LtdBSOFT | 51.7/100Mixed-positive evidence100% evidence | BASING | 19.8/35 Revenue 1.4% · PAT 21.1% · OPM change 4 pp 100% evidence | 13.0/25 ROCE 21.2% · OPM 16% 100% evidence | 14.5/20 P/E 14.6× · PEG 0.62 100% evidence | 4.4/20 RS sector -19.6% · RS bench -16.4% · 1Y -16.2%0 of 12 weeks ahead 100% evidence |
| Exact sum: 19.8 + 13 + 14.5 + 4.4 = 51.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 33Tata Consultancy Services LtdTCS | 51.3/100Mixed-positive evidence100% evidence | TURNING | 10.2/35 Revenue 7.7% · PAT 1.1% · OPM change -1 pp 100% evidence | 22.5/25 ROCE 63% · OPM 26% 100% evidence | 11.9/20 P/E 15.9× · PEG 1.85 100% evidence | 6.7/20 RS sector -17.8% · RS bench -14.9% · 1Y -22.2%0 of 12 weeks ahead 100% evidence |
| Exact sum: 10.2 + 22.5 + 11.9 + 6.7 = 51.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 34HCL Technologies LtdHCLTECH | 50.6/100Mixed-positive evidence82% evidence | TURNING | 12.3/35 Revenue 12.6% · PAT 2.6% · OPM change 0 pp 95% evidence | 19.0/25 ROCE 30.4% · OPM 20% 76% evidence | 9.0/20 P/E 20.4× · PEG — 50% evidence | 10.3/20 RS sector -9% · RS bench -5.6% · 1Y -7.8%3 of 12 weeks ahead 100% evidence |
| Exact sum: 12.3 + 19 + 9 + 10.3 = 50.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 35Sonata Software LtdSONATSOFTW | 50.4/100Mixed-positive evidence97% evidence | BREAKING OUT | 9.4/35 Revenue 4% · PAT 7.9% · OPM change 0 pp 95% evidence | 13.6/25 ROCE 30.7% · OPM 5% 95% evidence | 12.9/20 P/E 18.1× · PEG 0.81 100% evidence | 14.5/20 RS sector -0.7% · RS bench 2.3% · 1Y -5%8 of 12 weeks ahead 100% evidence |
| Exact sum: 9.4 + 13.6 + 12.9 + 14.5 = 50.4 · Decision use: Price leads the evidence: RS versus the benchmark is 2.3%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 36Mastek LtdMASTEK | 50.4/100Mixed-positive evidence82% evidence | TURNING | 13.7/35 Revenue 6% · PAT 5% · OPM change 0 pp 95% evidence | 13.6/25 ROCE 18% · OPM 15% 76% evidence | 12.6/20 P/E 13× · PEG — 50% evidence | 10.5/20 RS sector -8.5% · RS bench -5.7% · 1Y -26.3%2 of 12 weeks ahead 100% evidence |
| Exact sum: 13.7 + 13.6 + 12.6 + 10.5 = 50.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 37RNIT AI Solutions LtdAUTOPALIND | 50.4/100Thin evidence · provisional55% evidence | TURNING | 16.8/35 Revenue 59.8% · PAT 66.7% · OPM change -0.6 pp 95% evidence | 14.6/25 ROCE 20.2% · OPM 35.3% 76% evidence | 9.0/20 P/E 51.8× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —4 of 12 weeks ahead 0% evidence |
| Exact sum: 16.8 + 14.6 + 9 + 10 = 50.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 38Capillary Technologies India LtdCAPILLARY | 50.3/100Mixed-positive evidence63% evidence | ASLEEP | 27.4/35 Revenue 27.8% · PAT 135.8% · OPM change 5.8 pp 100% evidence | 4.1/25 ROCE 3.4% · OPM 15.7% 100% evidence | 8.8/20 P/E 83.6× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —0 of 10 weeks ahead 0% evidence |
| Exact sum: 27.4 + 4.1 + 8.8 + 10 = 50.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 39Mphasis LtdMPHASIS | 50.0/100Mixed-positive evidence94% evidence | TURNING | 15.2/35 Revenue 13.7% · PAT 9.9% · OPM change -1 pp 100% evidence | 17.2/25 ROCE 22.1% · OPM 18% 100% evidence | 5.6/20 P/E 25.1× · PEG 2.19 100% evidence | 12.0/20 RS sector 1.1% · RS bench -1.5% · 1Y -5.6%2 of 10 weeks ahead 70% evidence |
| Exact sum: 15.2 + 17.2 + 5.6 + 12 = 50 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 40Hexaware Technologies LtdHEXT | 48.7/100Mixed-negative evidence94% evidence | BREAKING OUT | 14.3/35 Revenue 13% · PAT 1.2% · OPM change 4 pp 100% evidence | 17.7/25 ROCE 30.1% · OPM 16% 100% evidence | 10.7/20 P/E 24.6× · PEG 0.81 100% evidence | 6.0/20 RS sector -20.6% · RS bench -8.1% · 1Y -20.8%8 of 10 weeks ahead 70% evidence |
| Exact sum: 14.3 + 17.7 + 10.7 + 6 = 48.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 41Zensar Technologies LtdZENSARTECH | 47.7/100Mixed-negative evidence100% evidence | BASING | 15.8/35 Revenue 8% · PAT 15.3% · OPM change 0 pp 100% evidence | 13.6/25 ROCE 22.8% · OPM 15% 100% evidence | 13.8/20 P/E 14× · PEG 1.11 100% evidence | 4.5/20 RS sector -25.7% · RS bench -23.5% · 1Y -37.5%0 of 12 weeks ahead 100% evidence |
| Exact sum: 15.8 + 13.6 + 13.8 + 4.5 = 47.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 42XT Global Infotech LtdXTGLOBAL | 47.3/100Mixed-negative evidence61% evidence | 18.6/35 Revenue 85.4% · PAT 29.4% · OPM change -6.6 pp 53% evidence | 9.3/25 ROCE 7.5% · OPM 9.5% 71% evidence | 9.3/20 P/E 40.8× · PEG — 50% evidence | 10.1/20 RS sector 0% · RS bench -12.7% · 1Y -10.3%2 of 12 weeks ahead to 2026-03-29 70% evidence | |
| Exact sum: 18.6 + 9.3 + 9.3 + 10.1 = 47.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 43Unicommerce eSolutions LtdUNIECOM | 45.9/100Mixed-negative evidence74% evidence | BASING | 14.5/35 Revenue 38.4% · PAT 18.1% · OPM change -8.1 pp 95% evidence | 16.5/25 ROCE 21.1% · OPM 10.6% 95% evidence | 9.1/20 P/E 45.5× · PEG — 15% evidence | 5.8/20 RS sector -13.6% · RS bench -22.3% · 1Y -26.6%0 of 10 weeks ahead 70% evidence |
| Exact sum: 14.5 + 16.5 + 9.1 + 5.8 = 45.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 44Wipro LtdWIPRO | 44.7/100Mixed-negative evidence100% evidence | BASING | 12.9/35 Revenue 6.4% · PAT -1.7% · OPM change 0 pp 100% evidence | 15.0/25 ROCE 17.8% · OPM 19% 100% evidence | 13.2/20 P/E 13.8× · PEG 1.4 100% evidence | 3.6/20 RS sector -20.6% · RS bench -17.9% · 1Y -23%0 of 12 weeks ahead 100% evidence |
| Exact sum: 12.9 + 15 + 13.2 + 3.6 = 44.7 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 45Excelsoft Technologies LtdEXCELSOFT | 44.6/100Mixed-negative evidence60% evidence | ASLEEP | 12.0/35 Revenue 26.8% · PAT 4.2% · OPM change -1.8 pp 95% evidence | 12.1/25 ROCE 13.6% · OPM 16.3% 95% evidence | 10.5/20 P/E 17× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —1 of 10 weeks ahead 0% evidence |
| Exact sum: 12 + 12.1 + 10.5 + 10 = 44.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4663 Moons Technologies Ltd63MOONS | 42.3/100Thin evidence · provisional58% evidence | BREAKING OUT | 20.6/35 Revenue 100% · PAT -80% · OPM change 128 pp 71% evidence | 3.4/25 ROCE -3.7% · OPM -52% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 8.3/20 RS sector -21.5% · RS bench 6.9% · 1Y -13.9%8 of 11 weeks ahead 70% evidence |
| Exact sum: 20.6 + 3.4 + 10 + 8.3 = 42.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 47Innovana Thinklabs LtdINNOVANA | 39.2/100Mixed-negative evidence81% evidence | ASLEEP | 8.7/35 Revenue 26% · PAT -39% · OPM change -32.5 pp 95% evidence | 11.6/25 ROCE 16.4% · OPM 17.6% 95% evidence | 9.4/20 P/E 21.4× · PEG — 50% evidence | 9.5/20 RS sector 0.7% · RS bench -22.9% · 1Y -38.9%0 of 10 weeks ahead 70% evidence |
| Exact sum: 8.7 + 11.6 + 9.4 + 9.5 = 39.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 48Magellanic Cloud LtdMCLOUD | 38.7/100Mixed-negative evidence81% evidence | TURNING | 9.7/35 Revenue 13.7% · PAT 6.7% · OPM change -7 pp 95% evidence | 13.9/25 ROCE 19.8% · OPM 28% 95% evidence | 11.8/20 P/E 15× · PEG — 50% evidence | 3.3/20 RS sector -54% · RS bench -26.3% · 1Y -67.2%6 of 11 weeks ahead 70% evidence |
| Exact sum: 9.7 + 13.9 + 11.8 + 3.3 = 38.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 49Aurionpro Solutions LtdAURIONPRO | 37.6/100Mixed-negative evidence93% evidence | BASING | 13.1/35 Revenue 14.8% · PAT 5.1% · OPM change -3 pp 100% evidence | 10.6/25 ROCE 16.3% · OPM 17% 100% evidence | 9.9/20 P/E 19.4× · PEG 1.39 65% evidence | 4.0/20 RS sector -28.3% · RS bench -26.1% · 1Y -47.6%2 of 12 weeks ahead 100% evidence |
| Exact sum: 13.1 + 10.6 + 9.9 + 4 = 37.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 50Allied Digital Services LtdADSL | 35.5/100Mixed-negative evidence74% evidence | ASLEEP | 14.4/35 Revenue 19.1% · PAT 5.6% · OPM change 0 pp 95% evidence | 6.3/25 ROCE 7.4% · OPM 9% 95% evidence | 10.6/20 P/E 16.4× · PEG — 15% evidence | 4.2/20 RS sector -29.1% · RS bench -20.2% · 1Y -31.9%4 of 10 weeks ahead 70% evidence |
| Exact sum: 14.4 + 6.3 + 10.6 + 4.2 = 35.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 51Kellton Tech Solutions LtdKELLTONTEC | 34.2/100Adverse evidence87% evidence | ASLEEP | 10.0/35 Revenue 9.5% · PAT 9.6% · OPM change -1 pp 95% evidence | 9.7/25 ROCE 15% · OPM 11% 95% evidence | 11.8/20 P/E 8× · PEG — 50% evidence | 2.7/20 RS sector -28.3% · RS bench -26.2% · 1Y -46.7%0 of 12 weeks ahead 100% evidence |
| Exact sum: 10 + 9.7 + 11.8 + 2.7 = 34.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 52Mindteck (India) LtdMINDTECK | 32.6/100Adverse evidence87% evidence | ASLEEP | 7.9/35 Revenue -1.8% · PAT 0.3% · OPM change -1.7 pp 95% evidence | 10.4/25 ROCE 15.1% · OPM 7.8% 95% evidence | 11.7/20 P/E 17.2× · PEG — 50% evidence | 2.6/20 RS sector -20.5% · RS bench -17.6% · 1Y -5.9%5 of 12 weeks ahead 100% evidence |
| Exact sum: 7.9 + 10.4 + 11.7 + 2.6 = 32.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 53Moschip Technologies LtdMOSCHIP | 30.7/100Adverse evidence87% evidence | FADING | 7.7/35 Revenue 8.4% · PAT -33.6% · OPM change -3.9 pp 100% evidence | 7.0/25 ROCE 11% · OPM 8.2% 100% evidence | 3.6/20 P/E 127× · PEG 5.04 65% evidence | 12.4/20 RS sector 3% · RS bench -3.1% · 1Y 32.5%7 of 10 weeks ahead 70% evidence |
| Exact sum: 7.7 + 7 + 3.6 + 12.4 = 30.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 54Orient Technologies LtdORIENTTECH | 29.7/100Thin evidence · provisional54% evidence | ASLEEP | 15.1/35 Revenue — · PAT — · OPM change -0.5 pp 19% evidence | 2.4/25 ROCE 8.4% · OPM 6.7% 95% evidence | 9.0/20 P/E 47.2× · PEG — 15% evidence | 3.2/20 RS sector -20% · RS bench -17.2% · 1Y -7.2%0 of 12 weeks ahead 100% evidence |
| Exact sum: 15.1 + 2.4 + 9 + 3.2 = 29.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 55Quick Heal Technologies LtdQUICKHEAL | 18.8/100Adverse evidence69% evidence | ASLEEP | 6.2/35 Revenue -6.6% · PAT -80% · OPM change -22.1 pp 71% evidence | 1.8/25 ROCE -4.7% · OPM -39% 95% evidence | 10.0/20 P/E — · PEG — 0% evidence | 0.8/20 RS sector -35.9% · RS bench -34.5% · 1Y -47.7%6 of 12 weeks ahead 100% evidence |
| Exact sum: 6.2 + 1.8 + 10 + 0.8 = 18.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 56Covance Softsol Ltd544361 | 67.0/100Thin evidence · provisional49% evidence | 25.8/35 Revenue 43.5% · PAT 100% · OPM change 19.7 pp 62% evidence | 17.8/25 ROCE 31.4% · OPM 23.1% 76% evidence | 11.2/20 P/E 12.9× · PEG — 15% evidence | 12.2/20 RS sector — · RS bench 48.4% · 1Y — 25% evidence | |
| Exact sum: 25.8 + 17.8 + 11.2 + 12.2 = 67 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 57Exato Technologies Ltd544626 | 57.9/100Thin evidence · provisional38% evidence | 20.9/35 Revenue — · PAT — · OPM change 3.4 pp 45% evidence | 17.5/25 ROCE 26.8% · OPM 18% 76% evidence | 9.5/20 P/E 32.6× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y — 0% evidence | |
| Exact sum: 20.9 + 17.5 + 9.5 + 10 = 57.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 58Unified Data- Tech Solutions LtdUNIFIED | 55.9/100Thin evidence · provisional31% evidence | 16.9/35 Revenue — · PAT — · OPM change 1 pp 26% evidence | 18.8/25 ROCE 45.2% · OPM 15% 76% evidence | 10.2/20 P/E 18.6× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y 14.8%0 of 12 weeks ahead to 2026-03-08 0% evidence | |
| Exact sum: 16.9 + 18.8 + 10.2 + 10 = 55.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 59Metalic Technoforge LtdMETA | 53.0/100Thin evidence · provisional27% evidence | 16.2/35 Revenue — · PAT — · OPM change -2 pp 13% evidence | 17.1/25 ROCE 36.1% · OPM 8% 76% evidence | 9.7/20 P/E 25.3× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y -42.1%0 of 12 weeks ahead to 2026-03-08 0% evidence | |
| Exact sum: 16.2 + 17.1 + 9.7 + 10 = 53 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 60Kody Technolab LtdKODYTECH | 52.7/100Thin evidence · provisional48% evidence | BREAKING OUT | 15.2/35 Revenue — · PAT — · OPM change -5 pp 19% evidence | 13.1/25 ROCE 16.8% · OPM 29% 95% evidence | 8.7/20 P/E 119× · PEG — 15% evidence | 15.7/20 RS sector 11.5% · RS bench 59.2% · 1Y 84.6%8 of 10 weeks ahead 70% evidence |
| Exact sum: 15.2 + 13.1 + 8.7 + 15.7 = 52.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 61Trident Techlabs Ltdthis pageTECHLABS | 46.1/100Thin evidence · provisional40% evidence | 16.0/35 Revenue — · PAT — · OPM change -2 pp 15% evidence | 16.1/25 ROCE 26.7% · OPM 27% 71% evidence | 10.8/20 P/E 14.9× · PEG — 15% evidence | 3.2/20 RS sector -49.7% · RS bench -56.5% · 1Y -60%0 of 12 weeks ahead to 2026-03-29 70% evidence | |
| Exact sum: 16 + 16.1 + 10.8 + 3.2 = 46.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 62Veefin Solutions LtdVEEFIN | 45.3/100Thin evidence · provisional43% evidence | 17.7/35 Revenue — · PAT — · OPM change -5.1 pp 19% evidence | 10.6/25 ROCE 9.8% · OPM 19.7% 76% evidence | 9.6/20 P/E 27.7× · PEG — 15% evidence | 7.4/20 RS sector -7.2% · RS bench -18.7% · 1Y -24.3%0 of 12 weeks ahead to 2026-03-08 70% evidence | |
| Exact sum: 17.7 + 10.6 + 9.6 + 7.4 = 45.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 63ERP Soft Systems Ltd530909 | 44.3/100Thin evidence · provisional41% evidence | 19.8/35 Revenue 19.1% · PAT 100% · OPM change -1.1 pp 53% evidence | 8.0/25 ROCE 1.6% · OPM 1.7% 57% evidence | 8.9/20 P/E 74.9× · PEG — 15% evidence | 7.6/20 RS sector — · RS bench -47.6% · 1Y -55%0 of 12 weeks ahead to 2026-03-29 25% evidence | |
| Exact sum: 19.8 + 8 + 8.9 + 7.6 = 44.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 64IDream Film Infrastructure Company Ltd504375 | 38.4/100Thin evidence · provisional35% evidence | TURNING | 12.8/35 Revenue — · PAT 0% · OPM change — 33% evidence | 3.1/25 ROCE -9.2% · OPM -25.8% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 12.5/20 RS sector — · RS bench 117.6% · 1Y —6 of 6 weeks ahead 25% evidence |
| Exact sum: 12.8 + 3.1 + 10 + 12.5 = 38.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Trident Techlabs Ltd's share price today?
Trident Techlabs Ltd trades at ₹167, −73.7% over the past year. The company is valued at ₹289 Cr. The stock sits at the very bottom of its 52-week range (₹167–₹608), −56.7% versus its 200-day average. On the tape, the price is in a downtrend, 51 weeks in. — as of 14 August 2026.
What were Trident Techlabs Ltd's latest quarterly results?
Trident Techlabs Ltd reported revenue of ₹64.0 Cr and net profit of ₹11.0 Cr for the Sep 25 quarter. Revenue rose 204.8% and profit rose 266.7% year on year. Earnings per share were ₹6.59. The operating margin was 27.0%, 2.0 pp lower than a year earlier. — as of 14 August 2026.
What is Trident Techlabs Ltd's revenue?
Trident Techlabs Ltd reported revenue of ₹64.0 Cr in the Sep 25 quarter, +204.8% year on year. For the full FY25 fiscal year, revenue was ₹77.0 Cr (+5.5%). Over the last 4 years revenue compounded at 28.8% a year. — as of 14 August 2026.
What is Trident Techlabs Ltd's profit?
Trident Techlabs Ltd earned ₹11.0 Cr of net profit in the Sep 25 quarter, +266.7% year on year. Full-year FY25 profit was ₹12.0 Cr. The operating margin ran 27.0% in the latest quarter. — as of 14 August 2026.
What is Trident Techlabs Ltd's market cap?
Trident Techlabs Ltd's market capitalisation is ₹289 Cr at a share price of ₹167. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 14 August 2026.
What is Trident Techlabs Ltd's P/E ratio?
Trident Techlabs Ltd trades at a P/E of 14.9×, at the 13th percentile of its own 2-year range, against a long-run median of 48.8×. This is a comparison with the stock's own history, not a value call — as of 14 August 2026.
Does Trident Techlabs Ltd pay a dividend?
No — Trident Techlabs Ltd has recorded a dividend payout of 0% of profit in each of its last 5 reported fiscal years, so there is no payout history to quote. That is a reading of the filed annual statements, not an estimate. — as of 14 August 2026.
Is Trident Techlabs Ltd overvalued?
On its own history, Trident Techlabs Ltd looks cheap: its P/E of 14.9× has been cheaper only 13% of the time in 2 years (long-run median 48.8×). That is a percentile read against the stock's own past, not a price opinion or a direction call. One caveat: margins are the best this company has ever printed — cheap on record margins is not the same thing as cheap. — as of 14 August 2026.
Is Trident Techlabs Ltd growing?
Yes — Trident Techlabs Ltd is growing: latest-quarter revenue +204.8% year on year, profit +266.7%, and the margin −2.0 pp at 27.0%. The earnings engine currently reads: improving — as of 14 August 2026.
How is Trident Techlabs Ltd performing?
Trident Techlabs Ltd is in a downtrend, 51 weeks in. Its latest quarter's revenue rose 204.8% and profit rose 266.7% year on year. Against the NIFTY 500 it has been behind on a trailing-13-week view for 20 weeks. This describes what the data did, not a rating. — as of 14 August 2026.
Is Trident Techlabs Ltd in an uptrend?
No — the price is in a downtrend (week 51 of stage 4), trading −56.7% versus its 200-day average and at the very bottom of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 14 August 2026.
Is Trident Techlabs Ltd beating the market?
Not lately — on a trailing-13-week view Trident Techlabs Ltd is currently behind the NIFTY 500 (20 weeks and counting; last ahead the week of 2025-11-07), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 2.2 years the stock moved +62% against the NIFTY 500's +8% — ahead of the index over the full window. — as of 14 August 2026.
Will Trident Techlabs Ltd's share price go up?
This page publishes no price forecast for Trident Techlabs Ltd. What it measures instead: the share price is ₹167, the price is in a downtrend 51 weeks in. Its P/E of 14.9× sits at the 13th percentile of its own 2-year range. — as of 14 August 2026.
Who owns Trident Techlabs Ltd?
Promoters hold 68.0% of Trident Techlabs Ltd, foreign institutions 0.0%, domestic institutions 0.0% and the public 32.0% (latest quarter). The biggest move on the register over the last two years: Domestic institutions cut 12.4 points over 4 quarters. — as of 14 August 2026.
Does Trident Techlabs Ltd have too much debt?
No — Trident Techlabs Ltd's debt-to-equity is 0.22, and operating profit covers the interest bill 6×. FY25 borrowings were ₹13.0 Cr against equity of ₹58.0 Cr. The returns on this page are earned, not borrowed — as of 14 August 2026.
What is Trident Techlabs Ltd's capex?
Trident Techlabs Ltd spent ₹4.0 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY25 alone that was ₹3.0 Cr, with ₹0.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 14 August 2026.
What is Trident Techlabs Ltd's cash flow?
Trident Techlabs Ltd generated ₹16.0 Cr of operating cash flow in FY25 and ₹13.0 Cr of free cash flow after ₹3.0 Cr of capital spending. Reported profit that year was ₹12.0 Cr, so operating cash ran ahead of profit. Cash-flow resolution for India is annual. — as of 14 August 2026.
Is Trident Techlabs Ltd's profit real cash?
Not fully — over the last 3 fiscal years, 38% of Trident Techlabs Ltd's reported profit arrived as operating cash. In FY25, operating cash was ₹16.0 Cr against reported profit of ₹12.0 Cr. The cash then goes mostly into the working-capital cycle. Cash-flow resolution is annual — as of 14 August 2026.
Where is Trident Techlabs Ltd in its business cycle?
Trident Techlabs Ltd's FY25 operating margin was 25.0%, against a 5-year band of 15.0%–25.0%: the top of the band — a record year. Record profitability is late-cycle territory: every ratio flatters at the top, and the story leans on margins holding. The latest quarter ran 27.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 14 August 2026.
What could break the Trident Techlabs Ltd story?
The sharpest disagreement: profits are rising, but only 38% of the last 3 years' profit arrived as operating cash — the gap between the P&L and the bank account is the thing to watch. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 14 August 2026.
Is Trident Techlabs Ltd a stock worth studying right now?
This is not investment advice. The machine read: Trident Techlabs Ltd's earnings have outrun its stock. EPS grew +22.7% in a year against a −73.7% price move. The sharpest open question: whether the cash starts following the profit. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 14 August 2026.